73 related articles for article (PubMed ID: 9815897)
1. Prognostic significance of the receptor for urokinase plasminogen activator in breast cancer.
Grøndahl-Hansen J; Peters HA; van Putten WL; Look MP; Pappot H; Rønne E; Dano K; Klijn JG; Brünner N; Foekens JA
Clin Cancer Res; 1995 Oct; 1(10):1079-87. PubMed ID: 9815897
[TBL] [Abstract][Full Text] [Related]
2. Prognostic significance of urokinase plasminogen activator and plasminogen activator inhibitor-1 mRNA expression in lymph node- and hormone receptor-positive breast cancer.
Leissner P; Verjat T; Bachelot T; Paye M; Krause A; Puisieux A; Mougin B
BMC Cancer; 2006 Aug; 6():216. PubMed ID: 16945123
[TBL] [Abstract][Full Text] [Related]
3. The prognostic value of the soluble urokinase-type plasminogen activator receptor (s-uPAR) in plasma of breast cancer patients with and without metastatic disease.
Nijziel MR; Van Oerle R; Hellenbrand D; Van Pampus EC; Hillen HF; Hamulyák K
J Thromb Haemost; 2003 May; 1(5):982-6. PubMed ID: 12871365
[TBL] [Abstract][Full Text] [Related]
4. Plasminogen activator inhibitor-1 is an independent prognostic factor of ovarian cancer and IMD-4482, a novel plasminogen activator inhibitor-1 inhibitor, inhibits ovarian cancer peritoneal dissemination.
Nakatsuka E; Sawada K; Nakamura K; Yoshimura A; Kinose Y; Kodama M; Hashimoto K; Mabuchi S; Makino H; Morii E; Yamaguchi Y; Yanase T; Itai A; Morishige KI; Kimura T
Oncotarget; 2017 Oct; 8(52):89887-89902. PubMed ID: 29163796
[TBL] [Abstract][Full Text] [Related]
5. Serum uPAR as Biomarker in Breast Cancer Recurrence: A Mathematical Model.
Hao W; Friedman A
PLoS One; 2016; 11(4):e0153508. PubMed ID: 27078836
[TBL] [Abstract][Full Text] [Related]
6. NFκB-Mediated Mechanisms Drive PEDF Expression and Function in Pre- and Post-Menopausal Oestrogen Levels in Breast Cancer.
Brook N; Gill J; Dharmarajan A; Chan A; Dass CR
Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555293
[TBL] [Abstract][Full Text] [Related]
7. Personalized Targeted Therapeutic Strategies against Oral Squamous Cell Carcinoma. An Evidence-Based Review of Literature.
Cao M; Shi E; Wang H; Mao L; Wu Q; Li X; Liang Y; Yang X; Wang Y; Li C
Int J Nanomedicine; 2022; 17():4293-4306. PubMed ID: 36134201
[TBL] [Abstract][Full Text] [Related]
8. The Urokinase Plasminogen Activation System in Pancreatic Cancer: Prospective Diagnostic and Therapeutic Targets.
Kumar AA; Buckley BJ; Ranson M
Biomolecules; 2022 Jan; 12(2):. PubMed ID: 35204653
[TBL] [Abstract][Full Text] [Related]
9. The Urokinase Receptor: A Multifunctional Receptor in Cancer Cell Biology. Therapeutic Implications.
Li Santi A; Napolitano F; Montuori N; Ragno P
Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33923400
[TBL] [Abstract][Full Text] [Related]
10. The Association between Plasma Levels of Intact and Cleaved uPAR Levels and the Risk of Biochemical Recurrence after Radical Prostatectomy for Prostate Cancer.
Stroomberg HV; Kristensen G; Drimer Berg K; Lippert S; Brasso K; Røder MA
Diagnostics (Basel); 2020 Oct; 10(11):. PubMed ID: 33126666
[TBL] [Abstract][Full Text] [Related]
11. The plasminogen activator inhibitor-1 paradox in cancer: a mechanistic understanding.
Kubala MH; DeClerck YA
Cancer Metastasis Rev; 2019 Sep; 38(3):483-492. PubMed ID: 31734763
[TBL] [Abstract][Full Text] [Related]
12. Prognostic Impact of Urokinase Plasminogen Activator Receptor Expression in Pancreatic Cancer: Malignant Versus Stromal Cells.
de Geus SW; Baart VM; Boonstra MC; Kuppen PJ; Prevoo HA; Mazar AP; Bonsing BA; Morreau H; van de Velde CJ; Vahrmeijer AL; Sier CF
Biomark Insights; 2017; 12():1177271917715443. PubMed ID: 28690396
[TBL] [Abstract][Full Text] [Related]
13. Spontaneous lung and lymph node metastasis in transgenic breast cancer is independent of the urokinase receptor uPAR.
Almholt K; Lærum OD; Nielsen BS; Lund IK; Lund LR; Rømer J; Jögi A
Clin Exp Metastasis; 2015 Aug; 32(6):543-54. PubMed ID: 26040548
[TBL] [Abstract][Full Text] [Related]
14. In vivo anti-metastatic effects of uPAR retargeted measles virus in syngeneic and xenograft models of mammary cancer.
Jing Y; Bejarano MT; Zaias J; Merchan JR
Breast Cancer Res Treat; 2015 Jan; 149(1):99-108. PubMed ID: 25519042
[TBL] [Abstract][Full Text] [Related]
15. Expression of uPAR in tumor-associated stromal cells is associated with colorectal cancer patient prognosis: a TMA study.
Boonstra MC; Verbeek FP; Mazar AP; Prevoo HA; Kuppen PJ; van de Velde CJ; Vahrmeijer AL; Sier CF
BMC Cancer; 2014 Apr; 14():269. PubMed ID: 24742002
[TBL] [Abstract][Full Text] [Related]
16. High concentration of urokinase-type plasminogen activator receptor in the serum of women with primary breast cancer.
Thielemann A; Baszczuk A; Kopczyński P; Kopczyński Z
Contemp Oncol (Pozn); 2013; 17(5):440-5. PubMed ID: 24596533
[TBL] [Abstract][Full Text] [Related]
17. A novel bispecific ligand-directed toxin designed to simultaneously target EGFR on human glioblastoma cells and uPAR on tumor neovasculature.
Tsai AK; Oh S; Chen H; Shu Y; Ohlfest JR; Vallera DA
J Neurooncol; 2011 Jun; 103(2):255-66. PubMed ID: 20830604
[TBL] [Abstract][Full Text] [Related]
18. uPAR and HER2 Genes Are Usually Co-Amplified in Individual Breast Cancer Cells from Blood and Tissues.
Uhr J
Breast Care (Basel); 2008; 3(s2):16-19. PubMed ID: 20824009
[No Abstract] [Full Text] [Related]
19. Tumor and vascular targeting of a novel oncolytic measles virus retargeted against the urokinase receptor.
Jing Y; Tong C; Zhang J; Nakamura T; Iankov I; Russell SJ; Merchan JR
Cancer Res; 2009 Feb; 69(4):1459-68. PubMed ID: 19208845
[TBL] [Abstract][Full Text] [Related]
20. Plasminogen activator inhibitor-1: the double-edged sword in apoptosis.
Balsara RD; Ploplis VA
Thromb Haemost; 2008 Dec; 100(6):1029-36. PubMed ID: 19132226
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
